Cargando…
Humoral response after SARS-CoV-2 mRNA vaccines in dialysis patients: Integrating anti-SARS-CoV-2 Spike-Protein-RBD antibody monitoring to manage dialysis centers in pandemic times
Dialysis patients are both the most likely to benefit from vaccine protection against SARS-CoV-2 and at the highest risk of not developing an immune response. Data from the medical field are thus mandatory. We report our experience with a BNT162b2-mRNA vaccine in a retrospective analysis of 241 dial...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491898/ https://www.ncbi.nlm.nih.gov/pubmed/34610031 http://dx.doi.org/10.1371/journal.pone.0257646 |
_version_ | 1784578822499205120 |
---|---|
author | Bachelet, Thomas Bourdenx, Jean-Philippe Martinez, Charlie Mucha, Simon Martin-Dupont, Philippe Perier, Valerie Pommereau, Antoine |
author_facet | Bachelet, Thomas Bourdenx, Jean-Philippe Martinez, Charlie Mucha, Simon Martin-Dupont, Philippe Perier, Valerie Pommereau, Antoine |
author_sort | Bachelet, Thomas |
collection | PubMed |
description | Dialysis patients are both the most likely to benefit from vaccine protection against SARS-CoV-2 and at the highest risk of not developing an immune response. Data from the medical field are thus mandatory. We report our experience with a BNT162b2-mRNA vaccine in a retrospective analysis of 241 dialysis patients including 193 who underwent anti-Spike-Protein-Receptor-Binding-Domain (RBD) IgG analysis. We show that a pro-active vaccine campaign is effective in convincing most patients to be vaccinated (95%) and frequently elicits a specific antibody response (94.3% after two doses and 98.4% after three doses). Only immunocompromised Status is associated with lack of seroconversion (OR 7.6 [1.5–38.2], p = 0.02). We also identify factors associated with low response (last quartile; IgG<500AU/mL): immunocompromised status, age, absence of RAAS inhibitors, low lymphocytes count, high C Reactive Protein; and with high response (high quartile; IgG>7000AU/mL): age; previous SARS-CoV-2 infection and active Cancer. From this experience, we propose a strategy integrating anti-spike IgG monitoring to guide revaccination and dialysis center management in pandemic times. |
format | Online Article Text |
id | pubmed-8491898 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-84918982021-10-06 Humoral response after SARS-CoV-2 mRNA vaccines in dialysis patients: Integrating anti-SARS-CoV-2 Spike-Protein-RBD antibody monitoring to manage dialysis centers in pandemic times Bachelet, Thomas Bourdenx, Jean-Philippe Martinez, Charlie Mucha, Simon Martin-Dupont, Philippe Perier, Valerie Pommereau, Antoine PLoS One Research Article Dialysis patients are both the most likely to benefit from vaccine protection against SARS-CoV-2 and at the highest risk of not developing an immune response. Data from the medical field are thus mandatory. We report our experience with a BNT162b2-mRNA vaccine in a retrospective analysis of 241 dialysis patients including 193 who underwent anti-Spike-Protein-Receptor-Binding-Domain (RBD) IgG analysis. We show that a pro-active vaccine campaign is effective in convincing most patients to be vaccinated (95%) and frequently elicits a specific antibody response (94.3% after two doses and 98.4% after three doses). Only immunocompromised Status is associated with lack of seroconversion (OR 7.6 [1.5–38.2], p = 0.02). We also identify factors associated with low response (last quartile; IgG<500AU/mL): immunocompromised status, age, absence of RAAS inhibitors, low lymphocytes count, high C Reactive Protein; and with high response (high quartile; IgG>7000AU/mL): age; previous SARS-CoV-2 infection and active Cancer. From this experience, we propose a strategy integrating anti-spike IgG monitoring to guide revaccination and dialysis center management in pandemic times. Public Library of Science 2021-10-05 /pmc/articles/PMC8491898/ /pubmed/34610031 http://dx.doi.org/10.1371/journal.pone.0257646 Text en © 2021 BACHELET et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Bachelet, Thomas Bourdenx, Jean-Philippe Martinez, Charlie Mucha, Simon Martin-Dupont, Philippe Perier, Valerie Pommereau, Antoine Humoral response after SARS-CoV-2 mRNA vaccines in dialysis patients: Integrating anti-SARS-CoV-2 Spike-Protein-RBD antibody monitoring to manage dialysis centers in pandemic times |
title | Humoral response after SARS-CoV-2 mRNA vaccines in dialysis patients: Integrating anti-SARS-CoV-2 Spike-Protein-RBD antibody monitoring to manage dialysis centers in pandemic times |
title_full | Humoral response after SARS-CoV-2 mRNA vaccines in dialysis patients: Integrating anti-SARS-CoV-2 Spike-Protein-RBD antibody monitoring to manage dialysis centers in pandemic times |
title_fullStr | Humoral response after SARS-CoV-2 mRNA vaccines in dialysis patients: Integrating anti-SARS-CoV-2 Spike-Protein-RBD antibody monitoring to manage dialysis centers in pandemic times |
title_full_unstemmed | Humoral response after SARS-CoV-2 mRNA vaccines in dialysis patients: Integrating anti-SARS-CoV-2 Spike-Protein-RBD antibody monitoring to manage dialysis centers in pandemic times |
title_short | Humoral response after SARS-CoV-2 mRNA vaccines in dialysis patients: Integrating anti-SARS-CoV-2 Spike-Protein-RBD antibody monitoring to manage dialysis centers in pandemic times |
title_sort | humoral response after sars-cov-2 mrna vaccines in dialysis patients: integrating anti-sars-cov-2 spike-protein-rbd antibody monitoring to manage dialysis centers in pandemic times |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491898/ https://www.ncbi.nlm.nih.gov/pubmed/34610031 http://dx.doi.org/10.1371/journal.pone.0257646 |
work_keys_str_mv | AT bacheletthomas humoralresponseaftersarscov2mrnavaccinesindialysispatientsintegratingantisarscov2spikeproteinrbdantibodymonitoringtomanagedialysiscentersinpandemictimes AT bourdenxjeanphilippe humoralresponseaftersarscov2mrnavaccinesindialysispatientsintegratingantisarscov2spikeproteinrbdantibodymonitoringtomanagedialysiscentersinpandemictimes AT martinezcharlie humoralresponseaftersarscov2mrnavaccinesindialysispatientsintegratingantisarscov2spikeproteinrbdantibodymonitoringtomanagedialysiscentersinpandemictimes AT muchasimon humoralresponseaftersarscov2mrnavaccinesindialysispatientsintegratingantisarscov2spikeproteinrbdantibodymonitoringtomanagedialysiscentersinpandemictimes AT martindupontphilippe humoralresponseaftersarscov2mrnavaccinesindialysispatientsintegratingantisarscov2spikeproteinrbdantibodymonitoringtomanagedialysiscentersinpandemictimes AT periervalerie humoralresponseaftersarscov2mrnavaccinesindialysispatientsintegratingantisarscov2spikeproteinrbdantibodymonitoringtomanagedialysiscentersinpandemictimes AT pommereauantoine humoralresponseaftersarscov2mrnavaccinesindialysispatientsintegratingantisarscov2spikeproteinrbdantibodymonitoringtomanagedialysiscentersinpandemictimes |